stockrow
Saturday 7 November 2026
Export SPRY’s income statement to Excel — free account
ARS Pharmaceuticals, Inc.
SPRY Healthcare Biotechnology
ARS Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $84.3 million, down 5.46% from fiscal 2024.
- Revenue
- +16.0%
- EPS
- +30.8%
- Free cash flow
- +36.5%
- Total debt
- +138.5%
Quarter to September 2026, against a year earlier
2.79
0.14
+5.28%
Follow SPRY
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
— | — | 1 | — |
| (92.38%) | (136.47%) | (210.37%) | 0.00% | ||
| (50.50%) | (64.42%) | (76.54%) | 0.00% | ||
ROIC |
(296.82%) | (401.19%) | (335.65%) | 0.00% | |
Return on Tangible Assets |
(69.05%) | (100.08%) | (141.07%) | 0.00% | |
Average Days of Receivables |
109.78 | 105.69 | 146.21 | 157.66 | |
Free Cash Flow per Share |
(1.89) | (1.76) | (1.98) | (1.84) | |
Free Cash Flow |
(186.56) | (175.07) | (196.40) | (183.07) | |
Capital Expenditures |
(15.70) | — | — | — | |
| Other line items | |||||
Cash ROIC |
(35.35%) | (40.39%) | (59.89%) | (144.84%) | |
Accounts Receivable Turnover |
5.03 | 5.21 | 3.25 | 2.74 | |
Accounts Payable Turnover |
0.67 | 0.68 | 0.64 | 0.00 | |
Inventory Turnover |
3.01 | 3.18 | 3.28 | — | |
Average Days of Payables |
678.21 | 687.72 | 651.26 | 0.00 | |
Days of Inventory on Hand |
149.57 | 125.64 | 127.45 | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
15.64% | 14.71% | 13.02% | 25.17% | |
Selling, General and Administrative Expense of Revenue |
273.05% | 263.90% | 243.30% | 207.36% | |
Share Based Compensation of Revenue |
26.22% | 24.47% | 26.72% | 27.57% | |
Interest Coverage |
— | (51.22) | (33.98) | — | |
Operating CF/Net income |
1.00 | 0.88 | 0.91 | 0.00 | |
Depreciation/Fixed assets |
(1.69) | (1.34) | (1.01) | 0.00 | |
Capex/Depreciation |
3.78 | 0.00 | 0.00 | — | |
Revenue per Share |
0.86 | 1.00 | 1.18 | 1.23 | |
Operating CF per Share |
(1.73) | (1.76) | (1.98) | (1.84) | |
Capex per Share |
(0.16) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.19 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026